PERTH, AU, Dec 12, 2019 - (ACN Newswire) - Holista CollTech (ASX: HCT, Holista) today announced that it has filed its
100%-owned global patent for platform technology that will deliver many fat-soluble medications by creating a
water-soluble delivery system. This patented process can apply to a whole range of molecules including the Cannabidiol
(CBD) oil industry.
The commercial benefits for the CBD producers include making their CBD formulation up to 40 times more potent (allowing
them to reduce their dosages significantly) as well as making their product palatable for the young and the elderly.
Fat-soluble molecules have poor bioavailability as they don't dissolve well and reach the bloodstream. As such, a higher
dosage needs to be ingested. This is both wasteful and costly. The platform technology will particularly benefit the
Cannabidiol (CBD) oil industry where the active material is scarce, costly and poorly water-soluble.
In a statement released this week, by our Project Leader and head of Holista's Technical Advisory Panel, Dr Roscoe Moore
Jr stated "Working on developing this technology is exciting. Most medicine consumed orally is wasted due to its poor
absorption by the body. This is especially true for CBD, which is also expensive. More important, the integrity of the
final molecule is preserved exactly as it is found in nature and hence, there is no apparent need for any lengthy
approvals process anywhere in the world. We only use materials certified as 'Generally Regarded as Safe' (GRAS) by the
FDA[1]."
Dr Moore is the retired Assistant Surgeon General of the United States. He currently sits on several Company boards
linked to CBD in the United States and Canada.
CBD Oil has an earthy, musky and lingering bitter taste due to the high concentration of organic compounds that make it
very unpalatable. This makes formulating CBD for oral consumption difficult. The taste masking technology linked to this
patented formulation used GRAS botanicals to allow wider applications in pharmaceutical and food with oral dosing.
"Holista drew from parallel work done on the turmeric molecule which is also very fat soluble" said Dr Swanand Malode,
leader the teams in Europe and Asia that worked on this technology for more than five years.
"We note that there is growing consensus in the medical community that CBD can be used to improve patient outcomes for
conditions such as seizure, inflammation, pain, psychosis or mental disorders, inflammatory bowel disease, nausea,
migraines, depression, anxiety" said Dr Rajen Manicka, CEO of Holista.
Holista is focused on fat-soluble substances such as CBD, curcumin and Vitamin D, targeting initially the food and
nutraceutical markets in Australia and North America.
According to a new estimate from cannabis industry analysts the Brightfield Group[2], the hemp-CBD market alone could
hit $22 billion by 2022. The prospects for Australia are also increasing. According to a 2016 University of Sydney
report[3], "Medicinal Cannabis in Australia: Science, Regulation & Industry", found that the Australian medicinal cannabis market, if it emulates cannabis regulations in Netherlands and
Canada, may produce demand for as much as 8,000 kg of product. Australia approved medical cannabis in 2016 and is
working towards liberalising this space further.
CBD, a non-psychoactive cannabinoid found in cannabis, has had a surge in popularity. Unlike Tetrahydrocannabinol (THC)
the chemical compound that gives cannabis its psychoactive effects, CBD has been shown to help patients with Post
Traumatic Stress Disorder (PTSD), anxiety, Multiple Sclerosis and epilepsy - without having the harmful effects.
The patent was registered in the USA and filed for a global coverage, as US Filing No: 16/694,197 (the patent may be
viewed on the Holista website). Holista has instructed its patenting firm to secure all global strategic markets
world-wide.
With the patent filing completed, Holista has commenced negotiations with companies involved in CBD processing in North
America and expect these negotiations to complete in 2020, leveraging the expertise and network of Dr Moore Jr.
The commercial model will seek to charge an industry-standard formulation fee for non-exclusive access and then a
quarterly licensing fee and royalty based on wholesale pricing of the licensee product.
[1] FDA - Food and Drug Administration, USA
[2] For more information on the Brightfield Group, refer towww.brightfieldgroup.com
[3] Details of the study can be found at mgcpharma.com.au/wp-content/uploads/2016/03/mgc_whitepaper_final-sml.pdf